On November 19, 2024, Brian Stephenson, Secretary, Treasurer & Chief Financial Officer of BridgeBio Pharma Inc (BBIO, Financial), sold 4,156 shares of the company. Following this transaction, the insider now owns 93,758 shares of the company. The details of this transaction can be found in the SEC Filing.
BridgeBio Pharma Inc (BBIO) is a biotechnology company focused on developing transformative medicines to treat genetic diseases. The company aims to address unmet medical needs by targeting well-characterized genetic drivers of disease.
Over the past year, Brian Stephenson has sold a total of 8,311 shares and has not purchased any shares. The insider transaction history for BridgeBio Pharma Inc indicates that there have been no insider buys in the past year, while there have been 12 insider sells.
On the day of the recent sale, shares of BridgeBio Pharma Inc were trading at $22.41, giving the stock a market cap of $4.354 billion.
The GF Value of BridgeBio Pharma Inc is estimated at $36.11, resulting in a price-to-GF-Value ratio of 0.62. This suggests that the stock is considered a "Possible Value Trap, Think Twice" based on its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated using the following factors:
- Historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow that the stock has traded at.
- A GuruFocus adjustment factor based on the company’s past returns and growth.
- Future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
